Therefore, the safest surgical cytoreduction (including sPDT) of recurrent malignant gliomas, which are refractory to other treatment techniques, and gliomas, for which microsurgical resection is impossible, increases post-relapse life expectancy, especially in patients with recurrent glioblastomas without an IDH gene mutation [38]. The gene discussed is IDH1; the disease is central nervous system cancer.